Research Archives - Lewy Body Dementia Association

Should Medicare pay for the new Alzheimer’s treatment?

When the FDA approved aducanumab for early Alzheimer’s disease, they also required an additional clinical trial to generate more data on its safety and effectiveness. (See LBDA’s earlier position statement […]

NIH funds $35 million study of LBD risk factor

People with rapid eye movement (REM) sleep behavior disorder act out their dreams. While sleeping safely in bed, for example, they might throw up their arms to catch an imaginary […]

LBDA Issues Position Statement on Aducanumab

Key Highlights: The FDA approved marketing of aducanumab for the treatment of Alzheimer’s disease under a special accelerated approval process. Aducanumab has not yet been proven to slow the progression […]

LBDA Research Mentorship Program

The Lewy Body Dementia Association is interested in establishing a Research Mentorship Program. The goal of this program is to promote the continued development of newly trained clinician-researchers, or experienced […]

Statement from LBDA on Hallucination Treatment Rejected by FDA

The Lewy Body Dementia Association is deeply concerned about the recent ruling by the FDA in which it rejected ACADIA Pharmaceutical’s supplemental new drug application for pimavanserin for the treatment […]

LBD Biomarkers: Progress

LBDA’s Research Centers of Excellence (RCOE) program presented a virtual symposium on “biomarkers” on January 25, 2021. A biomarker is a biological sign that reveals the presence or severity of […]

Sitting in the “genetic cross-hairs” of Alzheimer’s and Parkinson’s

Study locates five genes that may play a critical role in Lewy body dementia. Source: National Institutes of Health In a study led by National Institutes of Health researchers, scientists […]

The Virtual Assessment in Lewy Body Dementia: Pandemic and Beyond – A Series of 3 Webinars in 2021

The COVID-19 pandemic necessitated transition of care to telemedicine due to public health concerns. Those with LBD represent a particularly vulnerable population to the complications of COVID-19 given advanced age […]

What’s in a Name? It Depends on Who’s Using It

What’s Alzheimer’s disease (AD)? A person off the street will probably describe a memory problem. A healthcare professional will likely say the same. In fact, AD is what happens at […]

LBDA Partners with Medscape

Despite being a common form of dementia, there is still a tremendous need for more physician education on Lewy body dementia (LBD). To address this issue, LBDA is proud to […]

Shifting into Virtual Mode for LBD Research Meetings

In February of 2020 B.C. (before COVID-19), LBDA planned to host/attend 3 day-long meetings related to LBD research in June in Cleveland, OH. And then the pandemic hit. So, we […]

New Research Definition of Mild Cognitive Impairment with Lewy bodies (MCI-LB)

Most people with Lewy body dementia (LBD) will experience mild changes in thinking; over time, these symptoms, referred to as mild cognitive impairment (MCI), worsen and may become dementia. As […]

Alzheimer’s and Lewy bodies: When Two Pathologies Collide

DLB is one of two clinical diagnoses under the Lewy body dementia umbrella. When DLB co-occurs with Alzheimer’s disease, a clinical diagnosis is even more difficult to make as symptoms […]

LBD and Coronavirus: Prevention is the Best Medicine

With all of the news about the coronavirus and the condition “COVID-19,” here are some things that LBD families should keep in mind in the coming weeks and months. This […]

Loss of Attention May Suggest Faster Progression to Dementia in Very Early LBD

Like other dementias, a person doesn’t develop Lewy body dementia (LBD) overnight. Very mild symptoms worsen over time until medical attention is needed. Sometimes several years pass before these earliest […]

Biogen’s Aducanumab Clinical Trial Results Revealed

In a stunning reversal last October, pharma giant Biogen announced that its failed Phase 3 clinical trial of aducanemab in people with mild cognitive impairment or mild Alzheimer’s disease didn’t […]

Positive Results for the HARMONY Clinical Trial of Pimavanserin in Dementia-Related Psychosis

In December ACADIA Pharmaceuticals presented its top-line results from its Phase 3 clinical trial of pimavanserin in people who had dementia-related psychosis. The results had been eagerly awaited; ACADIA stopped […]

LBDA’s Contributions to the Scientific Community

Throughout the year, LBDA staff have been traveling across the country to promote discussion and awareness of Lewy body dementias in local communities and at national conferences. Here are just a […]

LBD Caregiver Experience Differs Between Spouses and Adult Children

Being a dementia caregiver can have a negative impact on one’s psychological well-being. But what is specifically known about the impact of LBD caregiving? And how it might differ based […]

Updated LBD Research Recommendations Published

Every 3 years, a national research summit is held to update research strategies for non-Alzheimer’s dementias. This 2-day national event is one of 3 rotating summits held in response to […]